rontalizumab   Click here for help

GtoPdb Ligand ID: 9640

Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial.
A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5].
Bioactivity Comments
Rontalizumab is broadly neutralizing of IFN-αs but not other Type I interferons [2].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IFN-α2 Hs Antibody Binding 10.7 pKd - 5
⤷ pKd 10.7 (Kd 1.8x10-11 M) [5]
IFN-α8 Hs Antibody Binding 10.7 pKd - 5
⤷ pKd 10.7 (Kd 2x10-11 M) [5]
IFN-α5 Hs Antibody Binding 10.5 pKd - 5
⤷ pKd 10.5 (Kd 3.1x10-11 M) [5]
IFN-α21 Hs Antibody Binding 10.3 pKd - 5
⤷ pKd 10.3 (Kd 4.6x10-11 M) [5]
IFN-α17 Hs Antibody Binding 9.5 pKd - 5
⤷ pKd 9.5 (Kd 3.3x10-10 M) [5]
IFN-α14 Hs Antibody Binding 9.3 pKd - 5
⤷ pKd 9.3 (Kd 5.2x10-10 M) [5]
IFN-α16 Hs Antibody Binding 9.1 pKd - 5
⤷ pKd 9.1 (Kd 7.2x10-10 M) [5]
IFN-α1/13 Hs Antibody Binding 9.1 pKd - 5
⤷ pKd 9.1 (Kd 8.3x10-10 M) [5]
IFN-α7 Hs Antibody Binding 8.9 pKd - 5
⤷ pKd 8.9 (Kd 1.3x10-9 M) [5]
IFN-α4 Hs Antibody Binding 8.2 pKd - 5
⤷ pKd 8.2 (Kd 6.5x10-9 M) [5]
IFN-α6 Hs Antibody Binding 8.0 pKd - 5
⤷ pKd 8.0 (Kd 1.09x10-8 M) [5]
IFN-α10 Hs Antibody Binding 7.4 pKd - 5
⤷ pKd 7.4 (Kd 3.54x10-8 M) [5]